In today’s NewsFlash roundup, Northeastern launches a new Master’s, a Sepracor drug trial comes up disappointingly inconclusive, and IMS Health gets a chief privacy officer.
• NH signs with ConEd for wind power
The energy contract runs through May 31, 2010, and moves the Granite State closer to its goal to have 25 percent of its power from renewable sources. ConEdison, based in White Plains, N.Y., said in a statement the wind power comes from developments across the U.S. The energy supplier purchases renewable energy credits that equate to the amount of electricity supplied to the state.
• Northeastern to launch clean energy-focused master’s degree
The program is intended to give engineers or technical business majors cross-disciplinary education in technologies that are sustainable and marketable. The program will comprise engineering and capital projects financing and will teach students how to integrate traditional energy systems with alternative systems using solar, wind, hydropower and photovoltaic technologies.
• Conn. reopens solar rebate program with new funds
The Connecticut Clean Energy Fund is once again accepting applications to its solar rebate program thanks to $3.1 million in fresh funding.
The rebate program, which provides rebates of up to 40 percent for installation of small solar photovoltaic systems, had been closed since November because all previous funding had been allocated. The new funding comes from a mix of federal stimulus funds and electricity ratepayer charges.
• Sepracor depression drug disappoints in trial
Drug maker Sepracor Inc. said it is determining whether to continue the development of its most advanced candidate for the treatment of depression after a Phase 2 clinical trial returned “inconclusive” results that fell short of the company’s initial goals.
• IMS Health names Kimberly Gray as chief privacy officer
Gray’s role entails privacy strategy, management and implementation in North America and South America. She is responsible for deciding on usage of the company’s market information, determining levels of privacy and transparency of information, and setting up safeguards to secure information.
• Interleukin Genetics to sell AJG Brands unit
Interleukin Genetics Inc., a Waltham-based genetic biomarker test maker, plans to sell AJG Brands Inc. for $4.6 million to Nutraceutical Corp. subsidiary Pep Products Inc. Interleukin plans to use the profits of the sale to develop and grow its genetic testing services and products.
Posted by Brendan Lynch
Tags: AJG Brands, ConEd, IMS Health, Interleukin, Northeastern University, Sepracor
RSS Feeds
